Linked Data API

Show Search Form

Search Results

1718118
registered interest false more like this
date less than 2024-05-14more like thismore than 2024-05-14
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Breast Cancer: Health Services remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government, further to the findings of the first quarterly report of the National Audit of Metastatic Breast Cancer, published on 10 April, what steps they are taking to address gaps in data collection for secondary breast cancer patients. more like this
tabling member printed
Baroness Merron more like this
uin HL4630 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-24more like thismore than 2024-05-24
answer text <p>It has not proved possible to respond to this question in the time available before Dissolution. Ministers will correspond directly with the Member.</p> more like this
answering member printed Lord Markham remove filter
question first answered
less than 2024-05-24T13:50:50.41Zmore like thismore than 2024-05-24T13:50:50.41Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
347
label Biography information for Baroness Merron more like this
1718119
registered interest false more like this
date less than 2024-05-14more like thismore than 2024-05-14
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Breast Cancer: Health Services remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what steps they are taking to improve the collection and reporting of ethnicity data for breast cancer patients to support understanding of variations in outcomes and patient experience of NHS care. more like this
tabling member printed
Baroness Merron more like this
uin HL4631 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-21more like thismore than 2024-05-21
answer text <p>Reducing inequalities and improving breast cancer outcomes for ethnic minority women is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including for breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.</p><p>NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in the operational planning guidance for the health system. The Core20PLUS5 approach proactively targets groups that are less likely to engage with services in the most deprived quintile of the population, along with ethnic minority communities and inclusion health groups, across five clinical areas which includes early cancer diagnosis, specifically screening and early referral.</p><p>The issue of improving equality monitoring, by reference to ethnicity and the other eight protected characteristics, is being considered at a national level under the programme called the Unified Information Standard for Protected Characteristics (UISPC). Evaluating the use of the 2021 ethnicity census categories is part of this programme. The UISPC Publication Steering Group is reporting to NHS England and the Department this year, which will inform a view on the next steps, including any plans for publication and consultation, and an implementation timetable. Preparatory work has been undertaken by NHS England that would facilitate the introduction of the 2021 ethnicity codes, should a decision be made to adopt the 2021 ethnicity census codes, or to implement an alternative approach to ethnicity, if recommended.</p><p>NHS England’s operational planning guidance recognises the importance of improving the quality of data for patient characteristics. This is one of the five strategic priorities in their drive to reduce healthcare inequalities, as improved data quality will help to reveal health inequalities and inform action to address them. NHS England has therefore asked systems to continue to improve the collection and recording of ethnicity data across primary care, outpatients, accident and emergency, mental health, community services, and specialised commissioning.</p><p>NHS England’s National Disease Registration Service (NDRS) collects ethnicity data for all cancer patients through a variety of routine, national data feeds, including the Cancer Outcomes and Services Dataset, Hospital Episode Statistics data, and Patient Administration System data. The NDRS publishes key performance indicator data on the national registration statistics for England. The latest published indicator data, for invasive cancer cases excluding non-melanoma skin cancers, diagnosed in 2020, shows that ethnicity data is complete for 94.9% of cases.</p>
answering member printed Lord Markham remove filter
grouped question UIN HL4629 more like this
question first answered
less than 2024-05-21T11:11:25.45Zmore like thismore than 2024-05-21T11:11:25.45Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
347
label Biography information for Baroness Merron more like this
1611068
registered interest false more like this
date less than 2023-04-17more like thismore than 2023-04-17
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Breast Cancer: Health Services remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what assessment they have made of the accessibility of (1) medicines, and (2) clinical interventions, for secondary metastatic breast cancer in England. more like this
tabling member printed
Baroness Ritchie of Downpatrick more like this
uin HL7158 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-05-02more like thismore than 2023-05-02
answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP). For example, average times taken between licensing and the publication of NICE guidance for new medicines have been reduced from 10.2 months for 2017/18 to 3.1 months for 2022/23. The proportion of positive NICE recommendations increased from 79% in 2017/18 to 92% in 2022/23.</p><p>NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab deruxtecan and palbociclib, while allowing for the collection of further data on their clinical and cost effectiveness to inform a final NICE recommendation.</p><p>NICE published a surveillance review of its guideline on advanced breast cancer in January 2023. It concluded that the recommendations on biological therapy, chemotherapy, psychological support and preventing and managing complications will be updated. These updates will be scheduled into NICE’s work programme and will include equality impact assessments and consultation with stakeholders to ensure access issues are fully considered.</p><p>The NHS Cancer Programme has commissioned five new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 with the first outcomes expected in 2023/24. One of the five audits will cover primary and metastatic breast cancer.</p><p>The Department has not had specific discussions with the Devolved Governments. However, the Welsh Government and the Northern Ireland Department of Health have agreements in place with NICE to use their technology appraisals and clinical guidelines. NICE will engage with them to support implementation. Both NICE and the Scottish Medicines Consortium are permanent partners in ILAP. Decisions on how guidance is implemented is a matter for each Government.</p>
answering member printed Lord Markham remove filter
grouped question UIN HL7159 more like this
question first answered
less than 2023-05-02T16:08:20.447Zmore like thismore than 2023-05-02T16:08:20.447Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
4130
label Biography information for Baroness Ritchie of Downpatrick more like this
1611069
registered interest false more like this
date less than 2023-04-17more like thismore than 2023-04-17
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Breast Cancer: Health Services remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what discussions they have had with the devolved administrations regarding the accessibility of (1) medicines, and (2) clinical interventions, for secondary metastatic breast cancer. more like this
tabling member printed
Baroness Ritchie of Downpatrick more like this
uin HL7159 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-05-02more like thismore than 2023-05-02
answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP). For example, average times taken between licensing and the publication of NICE guidance for new medicines have been reduced from 10.2 months for 2017/18 to 3.1 months for 2022/23. The proportion of positive NICE recommendations increased from 79% in 2017/18 to 92% in 2022/23.</p><p>NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab deruxtecan and palbociclib, while allowing for the collection of further data on their clinical and cost effectiveness to inform a final NICE recommendation.</p><p>NICE published a surveillance review of its guideline on advanced breast cancer in January 2023. It concluded that the recommendations on biological therapy, chemotherapy, psychological support and preventing and managing complications will be updated. These updates will be scheduled into NICE’s work programme and will include equality impact assessments and consultation with stakeholders to ensure access issues are fully considered.</p><p>The NHS Cancer Programme has commissioned five new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 with the first outcomes expected in 2023/24. One of the five audits will cover primary and metastatic breast cancer.</p><p>The Department has not had specific discussions with the Devolved Governments. However, the Welsh Government and the Northern Ireland Department of Health have agreements in place with NICE to use their technology appraisals and clinical guidelines. NICE will engage with them to support implementation. Both NICE and the Scottish Medicines Consortium are permanent partners in ILAP. Decisions on how guidance is implemented is a matter for each Government.</p>
answering member printed Lord Markham remove filter
grouped question UIN HL7158 more like this
question first answered
less than 2023-05-02T16:08:20.5Zmore like thismore than 2023-05-02T16:08:20.5Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
4130
label Biography information for Baroness Ritchie of Downpatrick more like this